MARKET

FREQ

FREQ

Frequency Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

27.42
+0.12
+0.44%
Closed 16:00 12/03 EST
OPEN
27.55
PREV CLOSE
27.30
HIGH
28.24
LOW
26.97
VOLUME
66.54K
TURNOVER
--
52 WEEK HIGH
29.71
52 WEEK LOW
14.50
MARKET CAP
925.01M
P/E (TTM)
-39.6128
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Frequency Therapeutics Appoints Peter Pfreundschuh as Chief Financial Officer
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that it has named Peter P. Pfreundschuh as its new chief financial officer. Mr. Pfreundschuh will oversee the Company’s financial strategy and activities related to accounting, investor relations, business development and business operations.
Business Wire · 2d ago
The Daily Biotech Pulse: Revance's DAXI Regulatory Decision, Reata Slips On FDA Feedback, Liquidia Setback
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 24)
Benzinga · 11/25 12:35
The Daily Biotech Pulse: Alnylam's Oxluma Snags Early FDA Approval, DBV Chief Scientific Officer To Depart, Decision Day For Liquidia
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 23)
Benzinga · 11/24 13:12
Cramer Gives His Opinion On Workhorse, Rackspace Technology, More
On CNBC's "Mad Money Lightning Round," Cramer told a viewer to go ahead and buy Workhorse Group Inc (NASDAQ: WKHS).
Benzinga · 11/20 12:54
Analysts Are Betting On Frequency Therapeutics, Inc. (NASDAQ:FREQ) With A Big Upgrade This Week
Celebrations may be in order for Frequency Therapeutics, Inc. (NASDAQ:FREQ) shareholders, with the analysts delivering...
Simply Wall St. · 11/18 04:40
Frequency Therapeutics EPS beats by $0.16, beats on revenue
Frequency Therapeutics (FREQ): Q3 GAAP EPS of -$0.16 beats by $0.16.Revenue of $11.25M (-53.6% Y/Y) beats by $5.37M.Cash, cash equivalents and short-term investments of $224.2M.Press Release
Seekingalpha · 11/16 12:33
Frequency Therapeutics Announces Expanded FX-322 Clinical Development Program and Upcoming Day-90 Phase 2a Analysis
Company Will Report Data from Phase 2a Sensorineural Hearing Loss (SNHL) Study in Late Q1 2021 First Patient Dosed in Phase 1b Study of Age-Related Hearing Loss; Additional Phase 1b Study for Severe SNHL Patients to
Benzinga · 10/29 11:04
Introducing Frequency Therapeutics (NASDAQ:FREQ), A Stock That Climbed 66% In The Last Year
Frequency Therapeutics, Inc. (NASDAQ:FREQ) shareholders have seen the share price descend 11% over the month. While...
Simply Wall St. · 10/19 15:10
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of FREQ. Analyze the recent business situations of Frequency Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average FREQ stock price target is 32.33 with a high estimate of 36.00 and a low estimate of 27.00.
EPS
Institutional Holdings
Institutions: 91
Institutional Holdings: 19.43M
% Owned: 57.60%
Shares Outstanding: 33.73M
TypeInstitutionsShares
Increased
27
3.01M
New
19
209.76K
Decreased
19
359.34K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.41%
Pharmaceuticals & Medical Research
+0.49%
Key Executives
Chairman/Lead Director/Independent Director
Marc Cohen
President/Chief Executive Officer/Co-Founder/Director/Primary Contact
David Lucchino
Co-Founder/Chief Scientific Officer
Christopher Loose
Co-Founder/Vice President
Will Mclean
Co-Founder/Vice President
William Mclean
Chief Financial Officer
Peter Pfreundschuh
Chief Human Resource Officer
Wendy Arnold
Vice President - Finance/Vice President - Operations
Richard Mitrano
Vice President - Business Development
Ajay Rai
Other
Dana Hilt
Other
Carl LeBel
Independent Director
Timothy Barberich
Independent Director
Cynthia Feldmann
Independent Director
Michael Huang
Independent Director
Robert Langer
Independent Director
Joel Marcus
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About FREQ
Frequency Therapeutics Inc. is a United States-based clinical-stage progenitor cell activation (PCA) regeneration company. The Company is focused on developing small molecule drugs that activate progenitor cells within the body to restore healthy tissue. It uses its PCA technology to develop a pipeline of progenitor cell activators. It focuses on various therapeutic areas, such as hearing loss, skin disorders, muscle regeneration, and gastrointestinal diseases. Its lead program, FX-322, activates the regrowth of sensory cells in the inner ear to treat chronic noise induced hearing loss.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Frequency Therapeutics Inc stock information, including NASDAQ:FREQ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FREQ stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FREQ stock methods without spending real money on the virtual paper trading platform.